TCR-Mimic Nanobody Discovery for Peptide-MHC Targeting

Because peptide-MHC complexes often differ by only a few amino acids, TCRm discovery requires exceptional specificity and precise discrimination between closely related epitopes. Off-target recognition remains one of the primary challenges in TCRm development.

To support high-specificity pMHC targeting, our discovery workflows integrate specialized antigen presentation strategies, high-stringency screening approaches, and quantitative display technologies to enable efficient identification of TCR-mimic nanobody candidates.

Why Nanobodies for TCR-Mimic Discovery?

TCR-mimic discovery requires binders capable of recognizing highly specific peptide-MHC conformations while minimizing cross-reactivity. Nanobodies are particularly suitable for this application due to several unique properties.

Recognition of Conformational Epitopes

The compact VHH structure enables access to structurally restricted peptide-MHC surfaces.

High Specificity Potential

Nanobody-based screening strategies can support stringent selection against closely related pMHC complexes.

Excellent Engineering Flexibility

Suitable for TCRm-CAR, bispecific molecules, and targeted delivery applications.

Key Challenges in TCR-Mimic Discovery

TCRm discovery presents unique technical challenges compared with conventional antibody discovery.

High pMHC Similarity

Closely related peptide-MHC complexes require extremely selective binders.

Limited Epitope Accessibility

Peptide epitopes are partially buried within MHC grooves.

Off-Target Binding Risk

Cross-reactivity with unrelated peptide-MHC complexes must be minimized.

Functional Specificity Requirement

Binders must recognize physiologically relevant pMHC conformations on cell surfaces.

Advantages Our TCR-Mimic Discovery Strategy

High-Stringency Yeast Display Screening:

Positive selection against target pMHC complexes

Negative screening against related pMHC complexes

Real-time affinity-based sorting

Enrichment of highly specific clones

These approaches help enrich highly selective TCRm nanobody candidates while minimizing off-target recognition.

Screening Workflow for TCR-Mimic Nanobody Discovery

TCR-Mimic Nanobody Discovery for Peptide-MHC Targeting

Deliverables

Clients will receive:

TCR-mimic nanobody sequences

Specificity validation data

Expression-ready constructs (optional)

Comprehensive project report

Optional downstream services

Affinity maturation

Nanobody humanization

Typical Project Timeline

Stage	Deliverables	Timeline
Immunization	Serum titer report	8 weeks
Library construction	Immune phage or yeast display library	3–4 weeks
Library screening	TCR-mimic nanobody candidates	4-6 weeks
Optional candidate production	Purified VHH and expression-ready constructs	2–3 weeks
Optional validation	Specificity and cell-binding assays	2–4 weeks

Typical total timeline: Approximately 19–25 weeks depending on target complexity and screening requirements.

Why Choose Us

TCRm-Oriented Screening Design

Our workflows are specifically optimized for highly selective peptide-MHC recognition.

Advanced Specificity Selection Strategies

Integrated negative screening and quantitative sorting help reduce off-target binding risks.

End-to-End Development Support

From antigen preparation and screening to engineering and characterization.

FAQs

What is a TCR-mimic nanobody, and what is its research and clinical value?

TCR-mimic (TCRm) nanobodies are engineered single-domain antibodies that specifically recognize peptide epitopes presented by major histocompatibility complex (MHC) molecules on the cell surface. By recapitulating the target recognition mode of T-cell receptors (TCRs), they combine the intracellular target accessibility of small-molecule inhibitors with the high targeting specificity of monoclonal antibodies. This unique mechanism enables precise targeting of disease-driving intracellular antigens, including cancer neoantigens and viral epitopes, unlocking new therapeutic avenues for traditionally "undruggable" targets.

What are the main application scenarios for TCR-mimic nanobodies?

TCRm nanobodies are enabling tools for next-generation targeted therapeutics and diagnostics. Core applications include:
- Oncology: Precision targeting of mutated intracellular oncoproteins (e.g., KRAS G12D/V, p53 neoantigens) inaccessible to conventional monoclonal antibodies
- Neurodegenerative Disease: Detection of disease-specific pMHC signatures associated with Alzheimer’s and Parkinson’s disease, supporting early diagnosis and disease monitoring
- Infectious Disease: Targeting of viral peptide epitopes (e.g., SARS-CoV-2, influenza) presented on infected cells, enabling rapid therapeutic development
- Basic Immunology Research: Robust reagents for visualization of antigen presentation dynamics and immune synapse formation

How do you ensure the target specificity of TCR-mimic nanobodies?

Target specificity is the primary validation criterion for our TCRm nanobody discovery workflow. All lead candidates are counter-screened against a panel of homologous pMHC complexes to achieve single-amino-acid resolution of target discrimination. Binding performance is further validated via in vitro assays（cell-based systems and protein-based systems).

What advantages does your TCR-mimic nanobody platform have over traditional TCR biologics?

Relative to conventional soluble TCRs, which are limited by poor stability and challenging manufacturing, TCRm nanobodies exhibit superior thermal stability, facile expression in bacterial or yeast systems, and flexible engineering into bispecific and cytotoxic formats. These properties reduce R&D costs and enable scalable, consistent production for research and translational development projects.

What information is required to initiate a TCR-mimic nanobody project?

Project initiation requires the target peptide sequence, corresponding MHC allele information, and any available functional or structural data for the target. Custom pMHC complex preparation services are available as needed. Pre-project feasibility consultation is recommended to optimize target selection and project design.